These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

242 related articles for article (PubMed ID: 31661986)

  • 1. Biological therapy-associated adverse reactions in asthma: analysis of reporting to the Portuguese pharmacovigilance system.
    Sousa J; Taborda-Barata L; Monteiro C
    Expert Opin Drug Saf; 2020 Jan; 19(1):99-106. PubMed ID: 31661986
    [No Abstract]   [Full Text] [Related]  

  • 2. Safety of Biological Therapies for Severe Asthma: An Analysis of Suspected Adverse Reactions Reported in the WHO Pharmacovigilance Database.
    Cutroneo PM; Arzenton E; Furci F; Scapini F; Bulzomì M; Luxi N; Caminati M; Senna G; Moretti U; Trifirò G
    BioDrugs; 2024 May; 38(3):425-448. PubMed ID: 38489062
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The clinical benefit of mepolizumab replacing omalizumab in uncontrolled severe eosinophilic asthma.
    Chapman KR; Albers FC; Chipps B; Muñoz X; Devouassoux G; Bergna M; Galkin D; Azmi J; Mouneimne D; Price RG; Liu MC
    Allergy; 2019 Sep; 74(9):1716-1726. PubMed ID: 31049972
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A survey of spontaneous reporting of adverse drug reactions in 10 years of activity in a pharmacovigilance centre in Portugal.
    Marques J; Ribeiro-Vaz I; Pereira AC; Polónia J
    Int J Pharm Pract; 2014 Aug; 22(4):275-82. PubMed ID: 24188533
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and safety of treatment with biologicals (benralizumab, dupilumab, mepolizumab, omalizumab and reslizumab) for severe eosinophilic asthma. A systematic review for the EAACI Guidelines - recommendations on the use of biologicals in severe asthma.
    Agache I; Beltran J; Akdis C; Akdis M; Canelo-Aybar C; Canonica GW; Casale T; Chivato T; Corren J; Del Giacco S; Eiwegger T; Firinu D; Gern JE; Hamelmann E; Hanania N; Mäkelä M; Hernández-Martín I; Nair P; O'Mahony L; Papadopoulos NG; Papi A; Park HS; Pérez de Llano L; Posso M; Rocha C; Quirce S; Sastre J; Shamji M; Song Y; Steiner C; Schwarze J; Alonso-Coello P; Palomares O; Jutel M
    Allergy; 2020 May; 75(5):1023-1042. PubMed ID: 32034960
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparative effectiveness of mepolizumab and omalizumab in severe asthma: An indirect treatment comparison.
    Cockle SM; Stynes G; Gunsoy NB; Parks D; Alfonso-Cristancho R; Wex J; Bradford ES; Albers FC; Willson J
    Respir Med; 2017 Feb; 123():140-148. PubMed ID: 28137490
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A risk of serious anaphylatic reactions to asthma biologics: a pharmacovigilance study based on a global real-world database.
    Park S; Kim Y; Lee GH; Choi SA
    Sci Rep; 2023 Oct; 13(1):17607. PubMed ID: 37848636
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of the Efficacy of Omalizumab and Mepolizumab in Non-Steroidal Anti-Inflammatory Drug-Exacerbated Respiratory Disease.
    Cihanbeylerden M; Tuncay G; Kayıkçı H; Damadoglu E; Karakaya G; Kalyoncu AF
    Int Arch Allergy Immunol; 2024; 185(10):947-952. PubMed ID: 38865992
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Biologic treatment eligibility for real-world patients with severe asthma: The IDEAL study.
    Albers FC; Müllerová H; Gunsoy NB; Shin JY; Nelsen LM; Bradford ES; Cockle SM; Suruki RY
    J Asthma; 2018 Feb; 55(2):152-160. PubMed ID: 28622052
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Case study: A Combination of Mepolizumab and Omaluzimab injections for severe asthma.
    Dedaj R; Unsel L
    J Asthma; 2019 May; 56(5):473-474. PubMed ID: 29733738
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Anaphylaxis to Mepolizumab and Omalizumab in a Single Patient: Is Polysorbate the Culprit?
    Bergmann KC; Maurer M; Church MK; Zuberbier T
    J Investig Allergol Clin Immunol; 2020 Aug; 30(4):285-287. PubMed ID: 32723701
    [No Abstract]   [Full Text] [Related]  

  • 12. Inhaled Drug Therapy-Associated Adverse Reactions in Obstructive Respiratory Diseases: A Review of a Decade of Reporting to the Portuguese Pharmacovigilance System.
    Fonseca W; Monteiro C; Taborda-Barata L
    Int J Environ Res Public Health; 2021 Nov; 18(23):. PubMed ID: 34886135
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Biologics for asthma and risk of pneumonia.
    Matera MG; Ora J; Calzetta L; Rogliani P; Cazzola M
    J Asthma; 2024 Sep; 61(9):905-911. PubMed ID: 38294705
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Long-term Efficacy and Safety of Mepolizumab in Patients With Severe Eosinophilic Asthma: A Multi-center, Open-label, Phase IIIb Study.
    Lugogo N; Domingo C; Chanez P; Leigh R; Gilson MJ; Price RG; Yancey SW; Ortega HG
    Clin Ther; 2016 Sep; 38(9):2058-2070.e1. PubMed ID: 27553751
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Long-term "real-life" safety of omalizumab in patients with severe uncontrolled asthma: A nine-year study.
    Di Bona D; Fiorino I; Taurino M; Frisenda F; Minenna E; Pasculli C; Kourtis G; Rucco AS; Nico A; Albanesi M; Giliberti L; D'Elia L; Caiaffa MF; Macchia L
    Respir Med; 2017 Sep; 130():55-60. PubMed ID: 29206634
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mepolizumab (Nucala°) in asthma.
    Prescrire Int; 2017 Feb; 26(179):38-39. PubMed ID: 30726627
    [No Abstract]   [Full Text] [Related]  

  • 17. Real-world safety and efficacy of omalizumab in patients with severe allergic asthma: A long-term post-marketing study in Japan.
    Adachi M; Kozawa M; Yoshisue H; Lee Milligan K; Nagasaki M; Sasajima T; Miyamoto T; Ohta K
    Respir Med; 2018 Aug; 141():56-63. PubMed ID: 30053973
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Anti-IgE therapy for asthma: an audit at atertiary care centre in Saudi Arabia.
    Weheba IM; Abdelsayed AM; Arnaout RK; Zeitouni MO; Mobaireek KF; AlHarthi TB; Mobeireek AF
    Ann Saudi Med; 2018; 38(6):439-444. PubMed ID: 30531179
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Real-world Omalizumab and Mepolizumab treated difficult asthma phenotypes and their clinical outcomes.
    Fong WCG; Azim A; Knight D; Mistry H; Freeman A; Felongco M; Kyyaly A; Harvey M; Dennison P; Zhang H; Howarth P; Arshad SH; Kurukulaaratchy RJ
    Clin Exp Allergy; 2021 Aug; 51(8):1019-1032. PubMed ID: 33866615
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Paediatric adverse drug reactions following use of asthma medications in Europe from 2007 to 2011.
    Aagaard L; Hansen EH
    Int J Clin Pharm; 2014 Dec; 36(6):1222-9. PubMed ID: 25288145
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.